Global Companion Animal Specialty Drugs Market 2024-2028

Global Companion Animal Specialty Drugs Market 2024-2028
The companion animal specialty drugs market is forecasted to grow by USD 4553.55 mn during 2023-2028, accelerating at a CAGR of 6.68% during the forecast period. The report on the companion animal specialty drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in pet humanization, rising awareness about disease prevention and pet insurance, and rise in aging companion animal population.

Technavio's companion animal specialty drugs market is segmented as below:

By Distribution ChannelVeterinary hospitalsPet care clinicsPharmacy storesBy ProductVaccinesAntibioticsParasiticidesFeed additivesOthersBy GeographyNorth AmericaEuropeAsiaRest of World (ROW)This study identifies the enhanced companion animal specialty drug offerings as one of the prime reasons driving the companion animal specialty drugs market growth during the next few years. Also, increase in m and a in the animal companion specialty drugs market and rising obesity in companion animals will lead to sizable demand in the market.

The report on the companion animal specialty drugs market covers the following areas:Companion animal specialty drugs market sizingCompanion animal specialty drugs market forecastCompanion animal specialty drugs market industry analysisThe robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading companion animal specialty drugs market vendors that include Bayer AG, Beaphar Beheer BV, Bimeda Holdings Ltd., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Chanelle Pharma Group, Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Kyoritsuseiyaku Corp., LABORATORIOS CALIER S.A, Mars Inc., Merck and Co. Inc., Neogen Corp., Norbrook Laboratories Ltd., Tianjin ringpu bio-technology Co. Ltd., Vetoquinol SA, Virbac Group, Zenex Animal Health India Private Ltd., Zoetis Inc., and Orion Corp.. Also, the companion animal specialty drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.